Charming Shoppes Newswire

Comprehensive Real-Time News Feed for Charming Shoppes.

Results 1 - 20 of 23 in Charming Shoppes

  1. Coherus Biosciences To Present At Cowen and Company Health Care Conference On March 2Read the original story

    Monday Feb 23 | BioSpace

    Coherus BioSciences, Inc. , a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will present at the Cowen and Company 35th Annual Health Care Conference on Monday, March 2 at 4:10 pm ET in Boston. A live and archived webcast of the presentation will be available on the Investor Relations page of the Coherus website at http://investors.coherus.com .

    Comment?

  2. Lane Bryant sales up, but CEO says it can do betterRead the original story w/Photo

    Wednesday Feb 18 | Business Journal

    ... Jersey-based company acquired Columbus-based Lane Bryant, run by CEO Linda Heasley , in 2012 as part the Charming Shoppes Inc. portfolio. Jaffe said Lane Bryant shoppers are good customers, but it needs more of them and is improving products and ...

    Comment?

  3. Coherus BioSciences: A Sharp Increase, A Sharp Drop, Plus Collateral...Read the original story w/Photo

    Saturday Feb 14 | Seeking Alpha

    Sometimes I need to look over my shoulder for news, even if it does not come from the company itself. The enormous potential of stocks in this sector will make many shareholders lots of money, and this one is proving itself to be a true winner thus far.

    Comment?

  4. Coherus Biosciences To Present At Healthcare Conference On February 11Read the original story

    Wednesday Feb 4 | BioSpace

    Coherus BioSciences, Inc. , a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City. A live and archived webcast of the presentation will be available on the Investor Relations page of the Coherus website at http://investors.coherus.com .

    Comment?

  5. Coherus BioSciences: A Logical Answer With A Biological Molecule?Read the original story w/Photo

    Jan 7, 2015 | Seeking Alpha

    This poem commemorates the event at the North Bridge in Concord, Massachusetts, that signaled the 1775 beginning of the American Revolution in our effort to gain our independence from the British. A more recent example of a shot being fired, one that resonated across the now United States, was the shot by Express Scripts across the bow of pharmaceutical companies signaling the beginning of an effort by pharmacy benefit managers wanting to control the limits at which they are willing to reimburse new drugs without pricing being challenged by the payers.

    Comment?

  6. Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well PositionedRead the original story w/Photo

    Dec 30, 2014 | Seeking Alpha

    Biosimilars , also known as follow-on biologics , are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods. Biosimilars are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product There are numerous patents expiring over the next several years and some of the biggest selling biocentric drugs on the market are ready to be re-produced with "generics".

    Comment?

  7. Coherus Biosciences Reports Third Quarter 2014 Financial And Operating ResultsRead the original story

    Dec 15, 2014 | BioSpace

    Coherus BioSciences, Inc. , a late-stage clinical biologics platform company focused on the global biosimilar market, today reported financial results and reviewed corporate events for the quarter ended September 30, 2014. In July 2014, achieved a $15.0 million milestone for the initiation of a CHS-0214 biosimilar candidate) global psoriasis phase 3 study.

    Comment?

  8. Coherus BioSciences to Present at the J.P. Morgan Healthcare Conference on January 12Read the original story

    Dec 8, 2014 | PR-inside.com

    REDWOOD CITY, Calif., Dec. 8, 2014 -- Coherus BioSciences, Inc. , a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will present at the 33 Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, at 9:30 a.m. PT at the Westin St. Francis Hotel in San Francisco, CA. A live and archived webcast of the presentation will be available on the Investor Relations page of the Coherus website at investors.coherus.com .

    Comment?

  9. Coherus Biosciences To Host Earnings Conference Call On December 15Read the original story

    Dec 4, 2014 | BioSpace

    Coherus BioSciences, Inc. , a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, December 15, 2014, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2014 financial results and pipeline progress. Participating in the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frederic Viret, Chief Financial Officer.

    Comment?

  10. Coherus BioSciences to Host Earnings Conference Call on December 15Read the original story

    Dec 4, 2014 | PR-inside.com

    REDWOOD CITY, Calif., Dec. 4, 2014 -- Coherus BioSciences, Inc. , a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, December 15, 2014, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2014 financial results and pipeline progress. Participating in the call will be Denny Lanfear, President and Chief Executive Officer, and Jean- Frederic Viret, Chief Financial Officer.

    Comment?

  11. Coherus Biosciences Research Coverage Started at Cowen and CompanyRead the original story w/Photo

    Dec 1, 2014 | AmericanBankingNews.com

    Shares of Coherus Biosciences opened at 13.62 on Monday. Coherus Biosciences has a 52-week low of $12.70 and a 52-week high of $14.49.

    Comment?

  12. Movers and fakers: How 'desperate' life sciences IPOs hurt 'legitimate' offeringsRead the original story w/Photo

    Nov 10, 2014 | Business Journal

    The same week that CareDx completed its $40 million IPO in July, said CEO Peter Maag, Federal Reserve Chair Janet Yellen told Congress that biotechs were among overvalued stocks. I admit it: I'm an IPO profiler.

    Comment?

  13. Movers and fakers: How 'desperate' life sciences IPOs hurt 'legitimate' offeringsRead the original story w/Photo

    Nov 10, 2014 | Business Journal

    The same week that CareDx completed its $40 million IPO in July, said CEO Peter Maag, Federal Reserve Chair Janet Yellen told Congress that biotechs were among overvalued stocks. I admit it: I'm an IPO profiler.

    Comment?

  14. U.S. IPO Weekly Recap: 8 Companies Go Public With Strong Returns As 5 Delay IPOsRead the original story w/Photo

    Nov 9, 2014 | Seeking Alpha

    This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive.

    Comment?

  15. Coherus BioSciences Prices Initial Public Offering of $85 Million of Common StockRead the original story

    Nov 6, 2014 | PR-inside.com

    REDWOOD CITY, Calif., Nov. 6, 2014 -- Coherus BioSciences, Inc. announced today the pricing of its initial public offering of 6,296,300 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Coherus.

    Comment?

  16. Borderfree: A platform for future global e-commerceRead the original story

    Oct 13, 2014 | GuruFocus.com

    ... of BRDR since 2010. He had more than 20 years of experience in finance and operations. He spent a decade at Charming Shoppes Inc, a leading multi-brand, multi-channel apparel retailer. According to his biography on the Borderfree website, Ed was ...

    Comment?

  17. Anthony Romano to take over as Destination Maternity's CEORead the original story

    Aug 12, 2014 | Fibre2Fashion

    ... held executive leadership positions at major publicly-held retailers, including Ascena Retail Group, Inc., Charming Shoppes and ANN INC. He joined Charming Shoppes, Inc., a $2 billion, publicly traded specialty retailer, in 2009 as its executive ...

    Comment?

  18. Ed Krell resigns from Destination Maternity CEO postRead the original story

    Aug 11, 2014 | Chain Store Age

    Capping a turbulent summer for maternity apparel retailers, Destination Maternity CEO Ed Krell has resigned effective immediately, and will be replaced by Anthony Romano, former CEO of Charming Shoppes, Inc. Krell's departure was announced less than two weeks after his company's unsuccessful takeover of rival retailer Mothercare.

    Comment?

  19. Destination Maternity CEO steps downRead the original story w/Photo

    Aug 11, 2014 | Philly.com

    ... 52, has had executive-leadership positions at publicly held retailers, including Ascena Retail Group Inc., Charming Shoppes, and ANN INC. He joined Bensalem-based Charming Shoppes in 2009 as executive vice president of business transformation/global ...

    Comment?

  20. Body Central adds three new members to BoDRead the original story

    Aug 1, 2014 | Fibre2Fashion

    ... Group, Inc. in Montreal, QC. Prior to his tenure with Aldo, he was the EVP & Chief Supply Chain Officer at Charming Shoppes, Inc. Prior to serving Charming Shoppes, Mr. Eshelman was a partner in the retail practice at Alix Partners, LLP, a ...

    Comment?